Atrás
Rango del Día
$8.58
$8.95
Rango de 52 Semanas
$8.50
$14.87
Volumen
94,310
Promedio 50D / 200D
$10.90
/
$11.14
Cierre Anterior
$8.81
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (627 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -5.2 | 0.3 |
| P/B | 1.7 | 2.9 |
| ROE % | -44.7 | 3.7 |
| Net Margin % | — | 3.8 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.0 | 0.2 |
Precio Objetivo de Analistas
Hold
$21.67
+148.5%
Low: $18.00
High: $24.00
EPS Futuro
-$2.18
Ingresos Est.
0
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
-$2.31
-$2.31 – -$2.31
|
17 M | 1 |
| FY2029 |
-$2.08
-$2.08 – -$2.08
|
0 | 1 |
| FY2028 |
-$2.13
-$2.47 – -$1.63
|
0 | 5 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 |
Mehra Uneek
Chief Financial Officer
|
grant | 128,330 | — | — |
| Mar 10, 2026 |
Beltran Pedro
Chief Scientific Officer
|
grant | 256,670 | — | — |
| Mar 10, 2026 |
Ben Yong
Chief Med & Dev Officer
|
grant | 256,670 | — | — |
| Jan 1, 2026 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1,114,400 | — | — |
| Dec 10, 2025 |
Wallace Eli M.
Chief Executive Officer
|
sell | 1,114,400 | — | — |
| Oct 10, 2025 |
BridgeBio Pharma LLC
|
other | 784,720 | — | — |
| Oct 2, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1,614,400 | — | — |
| Aug 26, 2025 |
Mehra Uneek
Chief Financial Officer
|
grant | 633,570 | — | — |
| Aug 26, 2025 |
Ben Yong
Chief Med & Dev Officer
|
grant | 357,177 | — | — |
| Aug 26, 2025 |
Tipirneni Praveen P.
|
grant | 52,269 | — | — |
| Aug 26, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 499,731 | — | — |
| Aug 26, 2025 |
Bauer Jake
|
grant | 138,193 | — | — |
| Aug 26, 2025 |
Beltran Pedro
Chief Scientific Officer
|
grant | 357,177 | — | — |
| Aug 26, 2025 |
MCCORMICK FRANK
|
grant | 91,076 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
other | 8,344,252 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
sell | 460,814 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
grant | 10,950,408 | $10.72 | — |
| Aug 11, 2025 |
McKenna Mark C.
|
other | 60,000 | — | — |
| Aug 11, 2025 |
Schmid John P.
|
other | 60,000 | — | — |
| Aug 11, 2025 |
Holman Albert A III
|
other | 60,000 | — | — |
Puntos Clave
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -114.50M
PEG of 0.00 suggests growth is underpriced
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-44.70%
ROIC-26.43%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
0.01
Current Ratio12.14
Interest Coverage0.00
Valoración
P/E Ratio
-5.21
P/B Ratio1.70
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -134.04M |
| ROE | -44.70% | ROA | -29.90% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -114.50M |
| ROIC | -26.43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 12.14 |
| Interest Coverage | 0.00 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -5.21 | P/B Ratio | 1.70 |
| P/S Ratio | N/A | PEG Ratio | 0.00 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 697.89M | Enterprise Value | 326.97M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -134.04M | -74.28M | -64.70M | -3,520.0 | -43,357.0 |
| EPS (Diluted) | -4.30 | 0.46 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -610,000.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Income | -145.82M | -80.86M | -64.77M | -3,520.0 | -43,357.0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448.38M | 194.42M | 332,894.0 | 144,578.0 | 144,281.0 |
| Total Liabilities | 37.29M | 5.71M | 396,463.0 | 166,455.0 | 162,638.0 |
| Shareholders' Equity | 411.10M | 188.72M | -63,569.0 | -21,877.0 | -18,357.0 |
| Total Debt | 2.77M | 0.0 | 70,095.0 | 43,106.0 | 36,961.0 |
| Cash & Equivalents | 373.69M | 1.70M | 0.0 | 0.0 | 0.0 |
| Current Assets | 425.46M | 1.95M | 0.0 | 0.0 | 0.0 |
| Current Liabilities | 35.04M | 187,515.0 | 396,463.0 | 166,455.0 | 162,638.0 |